Aktive Positionen von Geoffrey E. Clark
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Ischemix, Inc.
 Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Vorsitzender | - | - |
Karriereverlauf von Geoffrey E. Clark
Ehemalige bekannte Positionen von Geoffrey E. Clark
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| CITIUS PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | - | 12.09.2014 |
Statistik
International
| Vereinigte Staaten | 3 |
Operativ
| Chief Tech/Sci/R&D Officer | 1 |
| Chairman | 1 |
Sektoral
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CITIUS PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Ischemix, Inc.
Ischemix, Inc. Pharmaceuticals: MajorHealth Technology Ischemix, Inc. is a privately-held drug development company based in an undisclosed location. The American company focuses on developing its family of cytoprotective compounds for serious diseases and conditions, with the primary focus being the development of its lead compound, CMX-2043, for the treatment of TBI. Ischemix is working to advance cytoprotective therapies. The company was founded in 1999 by Victor Shashoua, and David DeWahl has been the CEO of the company since 2013. | Health Technology |
- Börse
- Insiders
- Geoffrey E. Clark
- Erfahrung
